Capricor Therapeutics CAPR Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -56.4%— | -46.6%— | -107.8%— | —— | —— | |
| Return on invested capital | -83.2%— | -128.7%— | -206.8%— | —— | —— | |
| Liquidity | ||||||
| Current ratio | 8.4×+1.9× | 9×+1.2× | 3.6×-0.6× | 4.4×+3.0× | 6.5×+5.0× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0×0.0× | 0.2×+0.1× | 0×— | 0×— | |
| Per Share | ||||||
| Book value per share | $4.85+73.5% | $6.58+59.3% | $1.83-11.1% | $2.30+536% | $2.80+376% | |
| Valuation | ||||||
| Market capitalization | $1.75B+303% | $1.57B+150% | $329.62M-38.7% | $422.8M+177% | $433.47M+103% | |
| Price / book | 6.3×+2.9× | 5.1×+0.8× | 3.9×-3.9× | 4×— | 3.4×— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Capricor Therapeutics's ratios come from?
- Every ratio is computed from Capricor Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.